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Summary 
There is growing enthusiasm for the timely publication and sharing of clinical trial 
data. The rationale for open access includes greater transparency, reproducibility, and 
efficiency of the research enterprise. In cardiovascular diseases, routinely sharing clinical trial 
data would create opportunities for undertaking comparative effectiveness research, 
providing much needed evidence on how different interventions compare to each other on 
key outcomes. Access to individual patient-level data would strengthen the validity of such 
research. Novel methodological approaches like network meta-analyses using individual 
patient-level data could reliably compare interventions that have not been compared to each 
other in head-to-head trials. However, there are significant practical, methodological, 
financial, and legal challenges to this utopian open access that need to be continually 
addressed. Sharing clinical trial data openly will only occur when the previously tolerated 
process of clinical research involving direct ownership and secrecy is abandoned for a new 
culture in which medical science is open to all of its stakeholders. With this new culture, data 
will be accessible, reanalysis and further analysis will be considered commonplace, and 
comparative effectiveness research through novel synthesis approaches such as network 
meta-analysis can thrive—as long as measures are taken to adequately ensure the goal 
remains to promote public health. 
 
Background 
Currently, many trials remain unpublished and many outcomes in published trials 
remain unreported.1 According to a study of government-funded clinical trials, only 46% of 
studies were published within 30 months of completion.2 Moreover, publication bias is 
widespread, as studies with favorable or statistically significant results are more likely to be 
reported than are those with unfavorable or nonsignificant results.3-5 If trials with 
unfavorable results are published, it is often later than those with favorable results.6,7 Despite 
improvement in access to some unpublished study results through significant developments 
such as ClinicalTrials.gov, the results of many other studies remain unavailable.3 Publication 
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alone, however, does not resolve the issue of selective reporting biases; incomplete reporting 
of outcomes in published study results is common, with only one third to one half of 
defined outcomes ever being discussed in published reports.8 When compounded in reviews 
and clinical practice guidelines, these biases in publication are major threats to the validity of 
the medical literature.3 
 In the current landscape of medicine in which a multitude of treatments abound for 
several conditions, the need to determine which are the most efficacious is becoming 
increasingly apparent. Despite sophisticated methods of data analysis, publication and 
selective reporting biases greatly undermine evidence-based practice, and the knowledge 
contained in those unreported and partly-reported trials—successful or otherwise—leaves 
medical professionals and decision-makers without a full picture of a treatment’s 
effectiveness—or in extreme cases, without full knowledge of associated risks.9  
In this article, we discuss the rationale for publishing and making raw data from 
clinical trials available—which we also refer to as “open access”—the new norm, and some 
of the recent key developments towards achieving this goal. These recent developments are 
particularly relevant for cardiovascular diseases, as comparative effectiveness research is 
emerging as a new framework to cardiovascular disease research and delivery. As we 
elaborate in our article, while policies aimed at publishing clinical trial results in a timely 
manner are increasingly adopted, progress towards sharing individual patient-level data from 
clinical trials continues to face a number of practical, methodological, financial, and legal 
challenges, which should be carefully considered and addressed.  
 
Rationale for publishing and sharing trial data 
In the past few years, there have been numerous recent developments aimed at 
reporting study results in a timely manner and promoting wider access to anonymized data 
from clinical trials. While some of these stemmed from regulatory agencies, research funding 
bodies, and academic institutions, several pharmaceutical companies have also committed to 
publishing and sharing their clinical trial data (Box 1). There is emerging consensus from a 
range of stakeholders (international organizations, regulatory agencies, research funding 
bodies, academic institutions, and journals) around the need to publish all clinical trial results 
in a timely manner irrespective of outcome. Beyond publishing results, however, it is 
imperative to make raw data available for reanalysis. Progress on this front is more 
fragmented despite increasing enthusiasm for granting access to individual patient-level data 
from clinical trials. 
The primary rationale for these developments is clear: publication and selective 
reporting biases threaten evidence-based medicine. The reasons underlying non-publication 
of trial results are several, and primarily include non-submission of negative results by trial 
investigators due to lack of time, funds, or other resources.10,11 Irrespective of the reasons 
behind non-publication, there have been several cases of unpublished clinical data 
significantly altering the balance between benefit and harms for some drugs.12 For example, 
analysis of published and unpublished randomized trials could have revealed cardiovascular 
risk associated with rofecoxib over 3 years before the manufacturer's voluntary market 
withdrawal.13 Another key example is the systematic review performed by Whittington and 
colleagues, which combined both published and unpublished antidepressant drug trials to 
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determine their efficacy in children.14 While all published data showed favorable risk-benefit 
profiles, when unpublished data were taken into account, the potential harms outweighed 
any benefits. A similar review of antidepressant trials showed that despite 49% of all trials 
under review having negative results, 94% of all published trials had positive results.15 Doshi 
and colleagues (2013) suggest that “[p]lacing one’s trust in the published literature implicitly 
assumes that what we are seeing is not distorted and is complete.”16 Greater transparency 
within clinical research could assuage such concerns over publication and selective reporting 
biases.  
A key motivation granting access to individual patient-level data from clinical trials is 
that of reproducibility—an issue core to the scientific method itself. The ability to fully 
reanalyze trial data is a crucial step for verification of results and would greatly bolster public 
confidence in new treatments.16 Reproducibility goes hand-in-hand with transparency, as 
reanalysis of trial data will allow for the evaluation of the potential impact analytical methods 
may have on the trial outcomes themselves.17 The prospect of external scrutiny may also 
indirectly improve the quality of clinical trial conduct, and in particular primary data 
collection, management, and reporting. In any trial, reproducibility will enhance the validity 
of any potential findings; as the goal of medical research is to help patients and doctors make 
informed decisions, the findings must be “reproducible, but these are qualities that current 
peer review processes cannot assure.”18  
Another key rationale for open access to raw data is to improve the efficiency of the 
research enterprise, and more specifically, and drug development.19 Having access to full 
study reports and anonymized individual patient-level data serves to prevent a wasteful use 
of resources. In the case of false-positive outcomes, wide-adoption of the new treatment 
may be preempted and future studies may not be funded.20 A prudent use of resources 
would be to pool resources, and generate and use publically available datasets to ask different 
research questions. In drug development, open access to anonymized trial data would allow 
scientists to use old data to answer new questions and reduce duplication of efforts.21 And 
while “data-dredging” should be avoided, appropriate analyses can be performed, particularly 
when the scientific community is allowed critical review.22  
Having access to individual patient-level data would advance our understanding of the 
nuances of treatment effectiveness, and whether a given treatment works differently for 
different groups of individuals. Despite important limitations such as a lack of pre-specified 
hypotheses, subgroups defined by patient characteristics within a trial could be analyzed to 
explore if some patients experience differing treatment effects, potentially generating 
important hypotheses for future research.23,24 In fact, previous research has shown that what 
may be the best treatment overall, may cause worse outcomes in particular subgroups.25 It 
remains, however, that subgroup analysis is best suited when risks of poor outcomes vary 
widely due to patient characteristics.26 Although seemingly persuasive subgroup effects are 
often spurious, credible claims of differential treatment effects across subgroups could lead 
to an increase in  patient-centered care by using the most relevant evidence for each 
patient.27  
There is also an ethical justification for open access. Clinical research is inherently 
purposed with contributing to the greater body of medical knowledge for not only its 
benefit, but for the benefit of the patients it serves. Clinical trials would be impossible to 
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conduct without the expressed consent of the patients who will eventually use the treatments 
under investigation; therefore, there is an ethical obligation to use data from these trials to 
the fullest possible extent so as not to squander the philanthropy of the patients enrolled.12 
 
Box 1: A selected list of recent major developments on clinical data sharing 
 
Regulatory agencies: 
 European Medicines Agency (EMA): EMA’s landmark policy, developed with 
input from a range of stakeholders patients, providers, researchers, and the 
pharmaceutical industry in 2014, sets the stage for giving access to individual patient-
level data for research use. EMA is already granting access to full clinical study 
reports for all pharmaceutical products reviewed28,29  
 The United States Food and Drug Administration (FDA): As part of its 
Transparency Initiative, FDA is considering approaches to providing access to 
selected sets of anonymized individual patient-level data, which carry the potential to 
improve regulatory science and improve decision-making within the FDA.30 
However, unlike the EMA, FDA is currently not considering routine preparation and 
release of anonymized individual patient-level data from clinical trials31 
 
Research funding bodies: 
 The United States National Institute for Health (NIH): NIH Data Sharing 
Policies include polices from a number of agencies that fund clinical trials: National 
Heart, Lung, and Blood Institute, the National Institute of Mental Health, and the 
National Institute for Diabetes, Digestive, and Kidney Diseases. NIH policies require 
investigators of publicly funded research to submit data-sharing plans and deposit 
their data in an approved repository in a timely manner.32    
 UK Medical Research Council (MRC): MRC Policy on Data Sharing recognizes 
publicly-funded research data as a public good, and expects data arising from MRC-
funded research to be made available in a timely and responsible manner.33 MRC’s 
Clinical Trials Unit supports a controlled access approach whereby researchers make 
formal applications for data sharing, which are subsequently reviewed by independent 
reviewers.34 
 The Wellcome Trust recently commissioned a study elucidating the importance of 
data sharing, which focused on the potential impact of data sharing on future 
research.35 The Trust is also considering to establish a consortium to develop a global 
solution to facilitate access to trial data.36  
 Cancer Research UK:  Data sharing policy states that all data generated with Cancer 
Research UK funding should be considered for sharing whilst safeguarding 
intellectual property, the privacy of patients and confidential data.37 Approach to data 
sharing can depend on the type, size, complexity and sensitivity of data. 
 
Industry-academia collaboration: 
 Yale University Open Data Access Project (YODA): In 2011, Medtronic 
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partnered with Yale University researchers to conduct external reviews of its clinical 
trial data. This collaboration established procedures for widely sharing individual 
patient-level data from clinical trials.1,9,38 Recently, Johnson & Johnson also gave 
anonymized individual patient-level data from its pharmaceutical trials to researchers 
at YODA, who will give access to the data to other researchers who request it39  
 
Industry: 
 GSK was the first major pharmaceutical company in 2012 to establish a data sharing 
policy and give access to all anonymized individual patient-level data from its clinical 
trials on a secure website.40 Data access is granted following permission from an 
independent review panel  
 Astellas, Bayer, Boehringer Ingelheim, Eisai, Lilly, Novartis, Roche, Sanofi, 
Takeda, UCB and ViiV Healthcare joined forces with GSK to collectively sponsor 
clinicalstudydatarequest.com, an online repository for anonymized individual patient-
level data from several trials conducted by the sponsoring companies. The website 
grants access to researchers after they submit research proposals deemed appropriate 
by an independent review panel41 
 Pharmaceutical Research and Manufacturers of America (PhRMA) and 
European Federation of Pharmaceutical Industries and Associations (EFPIA) 
Joint Principles for Responsible Clinical Trial Data Sharing show a commitment from 
major pharmaceutical companies to allow qualified investigators, after review by an 
independent review panel, access anonymized individual patient-level data, clinical 
study reports, and research protocols—while calling for the publication of all trial 
results regardless of outcome42,43 
 Association of British Pharmaceutical Industry (ABPI) report discusses both the 
rationale for data sharing from all stakeholder perspectives and on how best to 
implement data sharing policies going forward44 
 
Non-governmental entities: 
 Institute of Medicine (IOM): In its landmark report on sharing clinical trial data 
published in January 2015, IOM outlined key recommendations to maximize benefits 
and minimize risks of data sharing by developing guidelines for relevant stakeholders; 
establishing a timeline for when data should be shared by whom; and calling for a 
governance body to manage the process going forward45 
 The Academy of Medical Sciences report “Clinical trials data sharing: science, 
privacy and ethics” discussed important issues surrounding the purpose of and 
optimal approaches for data sharing, as well as patient perspectives and consent46 
 
International organizations: 
 World Health Organization (WHO) statement on clinical trial results calls for 
disclosure of all results of trials of new medications to a clinical trial registry and 
publication within one year, regardless of outcome, in order to increase the 
transparency of drug innovation. It also encourages the collaborative sharing of data 
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sets when appropriate without recommending concrete steps to achieve this goal47,81 
 
Journals: 
 British Medical Journal (BMJ): Data sharing policy mandates sharing relevant 
anonymized individual patient-level data for all trials submitted for publication in the 
journal upon reasonable request47 
 Public Library of Science (PLOS): PLOS journals require investigators to make all 
data underlying their analyses (including anonymized individual patient-level data) 
fully available48 
 
Other: 
 The United Kingdom Parliamentary Office of Science and Technology’s 
Report on data sharing a) recommends achieving greater transparency in trial data, 
such as registration as a condition for ethical approval, and b) outlines potential 
solutions to issues surrounding sharing of individual patient-level data, including a 
gatekeeper model to monitor access and prevent inappropriate uses of data 49 
 Nordic Trial Alliance Working Group’s report on transparency and registration in 
clinical research in the Nordic countries outlines current data transparency practices 
and how they can be improved, including ensuring public access to individual patient-
level data after trial publication and establishing a council to oversee storage and 
dissemination of clinical trial data. The Group also calls for stakeholders to make 
“clear laws, regulations, and guidelines” establishing a lack of transparency and 
withholding data as a severe offense50,82 
 
Open access and comparative effectiveness research 
Publishing and sharing clinical trial data create opportunities for undertaking 
comparative effectiveness research so that previously unexplored questions can be tackled.25 
Comparative effectiveness research aims to provide evidence on how different interventions 
compare to each other on harms and benefits in order to improve the delivery of care. 
Increasingly, it is such comparative evidence that informs clinical practice guidelines.51 
Comparative effectiveness research in cardiovascular disease has become a priority for both 
investigators and policy makers.52 Gaps remain in the evidence base for treatments of 
common cardiovascular conditions such as atrial fibrillation, anticoagulant therapies, and 
ischemic heart disease.52  
Large trials comparing all possible treatments head-to-head remain the gold standard 
for comparative effectiveness assessments. Such large trials have already paid dividends to 
the field of cardiovascular medicine. In the Sudden Cardiac Death in Heart Failure Trial 
(SCD-HeFT), amiodarone was proved no better than the standard heart failure care, while 
implanted internal cardioverter defibrillators significantly reduced mortality.53 Similarly, the 
Bypass Angioplasty Revascularization Investigation Two, Diabetes Trial (BARI 2D) 
indicated no significant difference in rates of death and major cardiovascular events between 
prompt revascularization with intensive medical therapy and medical therapy alone or 
between insulin sensitization and insulin provision.54  
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Traditionally, large randomized head-to-head trials take a long time to complete, 
require large numbers of participants, and are therefore very costly. Recent advances in 
randomized controlled trial design aim to improve the operational complexity and lower the 
corresponding economic costs of undertaking large head-to-head trials. Randomized registry 
trial design, for example, leverages the advantages of randomized and observational studies 
so that data on relevant outcomes can be captured as part of observational registries or 
cohorts that are already underway with established and routine data collection mechanisms. 
Bayesian adaptive analytic approaches allow for flexibility in the design and analysis of 
randomized trials, for example by adding new experimental interventions and dropping less 
effective ones without restarting the trial. Such approaches have the potential to reduce the 
sample size and cost required to collect information on relevant outcomes in a timely 
manner.  
Despite potential efficiencies that can be obtained with such simple, practical, and 
adaptive trials, carrying out large randomized experiments may still be difficult in therapeutic 
areas with multiple treatment options. In such cases, it is not conceivable to invest in large 
head-to-head trials to compare all available treatment alternatives, e.g., to establish the 
comparative impact of all currently available statins on the incidence of type-2 diabetes. New 
large trials of current treatments may indeed be unnecessary when several other trials exist.55 
Systematic evidence review and synthesis methods, such as meta-analysis, offer an efficient 
alternative to use this existing trial evidence. In order to accomplish this task, however, 
access to all of the data concerning all relevant treatments is a necessity. While published 
summary data may be sufficient “when estimating a single pooled treatment effect or 
investigating study level characteristics,” further investigation, such as whether treatment 
effects are dependent on patient characteristics, demands access to individual patient-level 
data.56 Access to individual patient-level data on both outcomes and covariates can 
significantly strengthen the validity of relying on existing trial evidence when making 
inferences on the effectiveness of intervention alternatives. Meta-analyses incorporating 
individual patient-level data have long been established in cardiovascular research (see Box 
2).57-60 
Even when individual patient-level data are available for all trials of treatments for a 
disease, the majority are placebo-controlled and do not have active comparators. While this 
allows for direct, pair-wise comparison, it is often hard to determine which treatment is best 
from the results.51 Interpretation only becomes more difficult and less precise when the 
evidence is indirectly compared through multiple successive trials.51  
As increasing numbers of treatments become available for various conditions, the need for 
comparing multiple treatments becomes imperative. Relatively novel network meta-analysis 
methods can combine the findings of separate clinical trials to indirectly compare multiple 
interventions to each other, resulting in “more consistent assessment than simpler alternative 
approaches” and providing a ranking of treatments based on both benefits and harms.61 
Such network meta-analysis methods allow for the generation of more robust comparative-
effectiveness information and “at very limited cost as compared with that of head-to-head 
trials.”21 This type of analysis is particularly useful when other pair-wise meta-analyses do not 
provide consistent estimates of effectiveness for treatment choices, as it combines both 
direct and indirect comparisons, thus incorporating a large share of the evidence.55,61 
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Network meta-analyses would also be a valuable tool when exploring the comparative 
effectiveness of interventions with different components and combinations of 
components.62 As the findings of network meta-analyses have significant implications for 
decision makers, including coverage of certain treatments and procedures, all relevant 
comparators must be assessed in order to make adequately evidence-based decisions.55 It 
remains, however, that network meta-analysis relies on statistical inference when using 
indirect comparisons. Access to individual patient-level data can significantly strengthen such 
analyses.63  
Given the lack of clinical areas where there is accessible data available for all 
comparators, network meta-analyses adopting individual patient-level data remain rare.64-66 
Fortunately, recently developed methods allow the combination of study-level findings with 
individual patient-level data in network meta-analyses, allowing the benefits of open access 
to trial data to be leveraged whenever possible.67,68 Without access to individual patient-level 
trial data, network meta-analyses are confined to working with summary results in the 
published trials, severely limiting a powerful tool for comparative effectiveness research in 
both cardiovascular research and all of medicine.66 
 
Box 2: Selected key examples of meta-analyses in cardiovascular medicine using 
individual patient-level data 
 Comparison of short- and long-term dual antiplatelet therapy (DAPT) after drug-eluting 
stent implantation demonstrated similar rates of major adverse cardiac events but lower 
rates of bleeding after stent placement in short-term DAPT patients69 
 A study of the efficacy of β blockers in patients with concomitant atrial fibrillation and 
heart failure showed β blockers should not be used over rate-control medication or as the 
standard therapy to improve prognosis in these patients70 
 Investigation of blood pressure-lowering treatment based on cardiovascular risk revealed 
similar relative protection for all levels of cardiovascular risk, but greater risk reduction as 
baseline risk increases71 
 A study of blood cholesterol and vascular mortality exhibited that total cholesterol was 
positively associated with ischaemic heart disease mortality in middle and old age patients 
and at all blood pressure levels72 
 Van Walraven and colleagues73demonstrated in patients with nonvalvular atrial 
fibrillation, that when compared to aspirin, oral anticoagulant significantly decreased risk 
of all strokes and cardiovascular events but increased the risk of bleeding 
 Amiodarone Trial Meta-Analysis Investigators showed that prophylactic amiodarone 
reduces the rate of sudden/arrhythmic death in high-risk patients with recent myocardial 
infarction or congestive heart failure, resulting in an overall decrease of mortality74 
 
Challenges for sharing clinical trial data 
Important research opportunities exist for using individual patient-level data from 
clinical trials to understand how cardiovascular interventions compare to each other. The 
question has changed from whether data should be shared to how it should be shared.23 
However, the road to fully open access across medicine is not without its challenges that 
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need to be carefully considered. A well-orchestrated policy and research agenda is needed to 
create meaningful financial and non-financial incentives, thereby aligning the objectives, 
values, and needs of several stakeholders, and in particular those of patients, research 
funders, pharmaceutical industry, and regulatory agencies. 
Moving forward, chief among key concerns is data ownership. Does the organization 
or sponsor who originally funded the research own the data?  Does the principal investigator 
who developed the hypothesis, designed the study, and executed the trial and data collection 
have intellectual property rights? Or do clinical research data actually constitute a public 
good—especially when published—as no one can be excluded from the benefits of the 
findings?75  
The recent influential report from the US Institute of Medicine (IOM) offers 
important insights (Box 3). The IOM positions clinical trial data away from individual 
ownership and firmly into a public good, calling on everyone from funders and sponsors to 
scientific publications to do their part in promoting this culture of sharing. Additionally, the 
IOM recommends transparency for how and with whom data will be shared and proposes 
establishing independent review panels to review and grant data access requests, rather than 
data holders themselves. 45  
Indeed, this model of “controlled access” is emerging as the preferred strategy among 
key stakeholders including research funders, pharmaceutical industry, and regulatory 
agencies. For example, the MRC’s Clinical Trials Unit housed at the University College 
London strongly favors an approach whereby researchers make formal applications for data 
sharing, which are subsequently reviewed by an independent review panel according to the 
scientific merit of the proposed analysis.34 The Unit also highlights the feasibility challenges 
facing those responsible for routinely depositing individual patient-level data. Among recent 
major initiatives, Nordic Trial Alliance Working Group’s seminal report on data sharing 
remains unique in its recommendation for establishing a global, public data repository to 
which all anonymized clinical trial data can be routinely deposited for secondary use.82  
 
Box 3. IOM guiding principles of data sharing 
 Stakeholders of clinical trial data should make data sharing the new norm by engaging in a 
number of activities including, but not limited to: ensuring the privacy of trial participants, 
giving appropriate credit to the original trial investigators, producing scientifically valid 
secondary analyses, and protecting intellectual property45  
 Sharing of data should take place within specified times surrounding each stage of a trial: 
registration, completion, publication, and regulatory application when trials are for new 
products 
 Holders of clinical trial data should implement operational strategies that include using 
data use agreements and designating an independent review panel for data sharing 
 A multistakeholder collaborative effort should be undertaken to lead and govern the 
process for addressing practical challenges of making data sharing the new norm 
  
Pharmaceutical industry’s leadership in the timely publication and sharing of clinical 
trial data is imperative. Despite industry enthusiasm for transparency and open access, full 
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information from clinical trials may still be inaccessible as the quality and completeness of 
study protocols and clinical reports can vary, complicating efforts aimed at reproducibility 
and validation of trial findings. Approximately two thirds of clinical trials are sponsored by 
the industry, and large investments from pharmaceutical companies are needed to develop 
standards for content of the accessible reports.76 To incentivize pharmaceutical companies to 
participate in collaborative initiatives to improve data harmonization, future policy efforts 
should be aimed at assuaging pharmaceutical industry’s legal concerns for more widespread 
data sharing. Indeed, pharmaceutical companies may face legal challenges if re-analyses find 
unexpected results. It is therefore important to devise and implement necessary statutory 
safeguards such as legally binding data sharing agreements to protect the trial sponsors from 
potential future litigation on the basis of post-hoc analyses. Important exceptions to any legally 
binding agreement should include identification of fraud and deliberate misinterpretation of 
data.  
With increasing access to individual-patient data comes potential threats to the privacy 
of participants in the trials. While informed consent is required before enrollment in any 
trial, few (if any) consent forms include the potentiality of disclosure of individual patient-
level data to parties other than trial investigators and regulators, let alone the Internet 
through open access.34 Similarly, there are instances where consent is given through a parent 
for a child’s participation or through a guardian where the patient has dementia. There is 
additional concern where trials investigate rare or chronic diseases, as patient-level datasets 
will likely include potentially identifiable variables such as age, sex and geographic location.34 
This issue is compounded when data can only be anonymized at the risk of making the 
dataset unusable for further research. Emerging models for seeking consent from research 
participants could resolve these tensions.77  
Even with the benefits of having the totality of the evidence available through open 
access to clinical trial data, there are methodological challenges with using the individual 
patient-level data gained for comparative effectiveness research. Advanced statistical 
knowledge and expertise may be required to combine data from multiple trials conducted at 
different time points, by different sponsors, and measuring different outcomes in potentially 
diverse patient populations. Of key concern is the extent to which patient-level data may be 
missing in different randomized trials and how original trial investigators have dealt with 
missing data. New approaches are needed to quantify and validate the contribution of 
different trials into a combined dataset. Additional methodological issues reside with how to 
appropriately use all of the data once they are accessible.  
Network meta-analyses are particularly vulnerable to bias when the trials used are not 
comparable due to effect modifying or confounding variables, specifically when direct and 
indirect comparisons are used.78 If an imbalance in effect modifiers exist between the direct 
and indirect comparisons, the results will not be justifiable.55 Differences in the included 
trials’ populations or differences in the relevant treatment details for each trial can also 
impact the results.61 In addition, investigators performing network meta-analyses will face 
challenges when they encounter discrepancies in outcome definitions and measurement 
methods in different randomized trials. Whether widespread access to individual patient-
level data can alleviate these methodological concerns remains to be seen. As more data 
become available, there will be particular concern with combining historical and 
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contemporary trials, as patients in the historical trials may be more severely ill due to the 
advancement of medicine.51 Study populations may also have different underlying risks for a 
particular illness or trials may differ in their randomization or blinding procedures.79 
Additionally, meta-analyses are only as robust as the trials that comprise the evidence 
network. If one trial lacks internal or external validity the analysis will suffer.55,80  
Researchers must be discerning so as to avoid poor trial data—whether in general or 
just for the specific analysis—so that results will be valid, robust, and generalizable. The 
financial implications of addressing key methodological challenges of data sharing should not 
be underestimated. A new methodological research agenda is needed to develop and evaluate 
new methods for combining and analyzing new datasets. In the immediate term, large and 
sustained investments from governments and research funding bodies will be required to 
train the next generation of statisticians, investigators, and applied researchers who will 
increasingly encounter combined datasets with individual patient-level data obtained from 
different randomized controlled trials.  
 
Conclusion 
In the age of comparative effectiveness research, summary data from only published 
trials are inadequate to fully utilize the extensive investments sponsors and funders have 
made to medical research. Early believers in open access data have already brought us to the 
precipice of having truly open science in which researchers will have exciting opportunities 
for comparative research and the public will have renewed trust in scientific investigation. 
However, we must continue to build on the foundation provided by early adopters and work 
to establish the new “expected norm” of clinical trial data sharing. Comparative effectiveness 
research has already become the “bedrock” for creating clinical practice guidelines and in an 
age where spending on healthcare has only increased, access to the entirety of clinical trial 
data can propel comparative effectiveness research forward to improve clinical decision 
making.51  
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